GBT Appoints Kim Smith-Whitley, M.D., to Lead Research and Development
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that world-renowned...
News
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Best objective response rate of 87% reported for 15 patients with relapsed/refractory mantle cell lymphoma, with a median follow-up of...
scPharmaceuticals Inc. Receives Complete Response Letter from FDA for FUROSCIX®
CRL did not identify clinical deficienciesBURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company...
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
MAD: Average Change from Baseline in Serum Iron Through Day 7 Figure 1 MAD: Average Change from Baseline in Transferrin...
Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
Nes Ziona, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company,...
Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting
Expanded data set supports efficacy across key measures including complete remission and MRD(-) rates, duration of response and overall survival...
Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff
-- Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus plans buildout of its manufacturing capabilities to support...
Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020
SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused...
Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist’s Kitchen
NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Dec. 07, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire --Todos Medical (OTCQB: TOMDF),an in vitro diagnostics company focused on...
KBP Biosciences Meets Primary Endpoint for BLOCK-CKD Phase 2b Study of KBP-5074 for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease Patients
KBP-5074 Achieves 10.1 mmHg reduction in systolic blood pressure (SBP) at 0.5mg dose compared to placebo Positive diastolic blood pressure...
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for...
MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting
53.8% ORR in relapsed/refractory DLBCL patients Preliminary duration of response of up to 168 days observed, with six of seven...
Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System, a New Non-Daily, Non-Invasive Contraceptive Patch
Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N.J., Dec. 07,...
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Data presented at the 62nd American Society of Hematology (ASH) Annual Meetingshow extremely favorable safety profile and clinical activity 89%...
Kevin Muir Joins Delcath Systems, Inc. as VP, Commercial Operations
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the...
Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists
Supplemental Analyses of GALACTIC-HF Left: Forest plot of the primary composite endpoint for subgroups of patients with lower left ventricular...
Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study
Topline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021Sofpironium bromide gel, 5% (ECCLOCK®)...
VitalHub Subsidiary Transforming Systems Secured 5-Year Contract with NHS Herefordshire and Worcestershire CCG
TORONTO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce that...
NextGen Healthcare Client Bridges Health Partners Achieves Medicare Shared Savings of Nearly $20 Million
Leveraging NextGen® Population Health Solutions, Clinically Integrated Network Improves Quality of Patient Care While Exceeding Its Savings Objectives for Two...
LivaNova Announces Board Appointment and Board Leadership Changes
LONDON--(BUSINESS WIRE)--$LIVN--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a series of enhancements to the Company’s...